Clinical Trial

The Effects of Sleeve Gastrectomy on Fractalkine

Study acronym: CX3CL1
Completed
View on ClinicalTrials.gov →
Summary
Fractalkine (CX3CL1) is a unique chemokine involved in leukocyte adhesion, migration, and obesity-associated adipose tissue inflammation. Although bariatric surgery results in substantial weight loss and metabolic improvement, the temporal pattern of circulating CX3CL1 levels following laparoscopic sleeve gastrectomy (LSG) remains poorly understood. This study aimed to evaluate longitudinal changes in serum CX3CL1 levels after LSG and to investigate their association with postoperative weight loss.
Trial Details
NCT Number NCT07655739
Lead Sponsor Mehmet Buğra Bozan
Conditions Obesity & Overweight
Enrollment 40 participants
Start Date 2025-09-04
Primary Completion 2026-01-04 (estimated)
Study Completion 2026-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-18